P

Pfizer

Makes cancer drugs, vaccines and other medicines

NHS Solutions Partner

Full-TimeUpdated on 10/21/2026Deadline 10/24/26
No salary listed
Mid
Remote in UK
Remote
Project & Program ManagementProject Management

About the job

Requirements
  • Significant experience in account management, healthcare partnerships, or market access roles.
  • Strong understanding of NHS structures, commissioning, and funding flows in England and equivalent structures in the Devolved Nations.
  • Project management skills, including experience developing project initiation documents, business cases, and outcome frameworks or similar.
  • Experience in pathway or service redesign and change management support.
  • Ability to build trusted, senior-level relationships with NHS executives and clinical leaders.
  • Sound commercial and analytical judgement.
  • Working knowledge of the ABPI Code of Practice, especially Collaborative Working and Disclosure UK requirements.
  • Ability to translate local health system or NHS plan priorities into aligned therapeutic-area solutions that address challenges and optimise patient care.
  • Integrity and the ability to operate within a highly governed, audited environment, with attention to documentation and process.
  • Ability to translate a clinical or operational problem into a structured, fundable project proposal.
  • Ability to influence without direct authority across NHS and internal company stakeholders.
  • Resilience in managing projects that may run over 12–24 months amid shifting NHS priorities and reorganisations.
Responsibilities
  • Position Pfizer as a partner of choice in developing collaborative programmes with the NHS that address important issues and deliver meaningful impact.
  • Work with the cross-functional team and NHS stakeholders to identify service barriers, unmet need, or pathway inefficiencies where collaborative working could measurably improve patient care or system efficiency, including diagnosis, treatment, resource utilisation, economic impact, and patient experience or adherence.
  • Consider with NHS partners how digital and AI solutions could support pathway transformation.
  • Define measurable outcomes, processes for replication and scaling if outcomes are achieved, and plans for long-term sustainability.
  • Develop the Project Initiation Document, defining objectives, scope, each partner’s resource contributions, governance structure, outcome measures, timeline, and exit strategy.
  • Lead internal review of collaborative working projects with medical, legal, and compliance teams as required, and identify an appropriate Executive Sponsor.
  • Draft and negotiate the Collaborative Working Agreement with the correct NHS legal entity, including conflict-of-interest and dispute-resolution provisions.
  • Arrange document certification and publish a certified executive summary before project initiation in line with Code requirements.
  • Lead project delivery and chair or co-chair the project board or governance group.
  • Coordinate internal contributions from health economics, medical affairs, data and real-world evidence, digital and AI, and project management, as well as third-party delivery partners commissioned into the project.
  • Monitor progress against milestones and outcome measures, manage risks, variations, and dispute resolution under the agreement, and adjust accordingly.
  • Support funded NHS roles or service changes in transitioning toward sustainability, including contributing to a business case for continued local funding beyond the project end date.
  • Ensure activity remains non-promotional and is not, or perceived to be, an inducement to prescribe, supply, recommend, buy, or sell any medicine.
  • Ensure that collaborative projects that may increase appropriate medicine use in a pathway, including Pfizer medicines, align with local NHS guidance and national guidance where it exists.
  • Maintain complete documentation of resource contributions, governance decisions, and outcomes for audit purposes, and ensure there is no access to individual patient data.
  • Ensure accurate transfer-of-value data for annual Disclosure UK reporting.
  • Publish a final outcomes report or summary at project close, measuring agreed outcomes.
Desired Qualifications
  • Experience in local data analysis and clinical audit support to build the case for change.
  • Experience in service evaluation measurement and health economics to demonstrate system benefits.
  • Experience supporting implementation of technology and AI solutions in the NHS to improve care pathways, including patient identification, diagnosis or triage, remote monitoring, and e-PROMS.
  • Experience managing multi-partner projects involving third-party delivery organisations such as data/analytics or clinical staffing providers.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.